SURE-NAC™ does more than just treat the symptoms of inflammation; it could fight directly the cause of prominent diseases such as chronic obstructive pulmonary disease (COPD), Cystic Fibrosis, arthritis, and multiple sclerosis.

There are a number of diseases where inflammation is a major symptom. N-acetylcysteine (NAC) is a common anti-inflammatory drug prescribed to treat the inflammation as well as other symptoms. But its short-term effects merely treat the symptoms, while the underlying causes continue. Sufferers only ever find temporary relief, diminished by the side effects.

The team at Tiara Pharmaceuticals has designed a prodrug technology that improves the effectiveness while eliminating the side effects of the universally known generic anti-inflammatory drug, NAC.

We’ve incorporated the prodrug into an extended release formulation in order to provide prolonged therapeutic coverage for treatment of inflammatory diseases.

NAC’s unique well known properties have already shown great promise in recent human clinical trials for patients with COPD and Cystic Fibrosis. However, the effect of NAC is limited due to a short half life and servere side effects. SURE-NAC™ improves on this due to superior effectiveness, long life and reduced side effects.

When taken orally, SURE-NAC™ is chemically converted to the active drug in the GI tract and is taken up by the blood stream. Compared to NAC, the amount of SURE-NAC™ that is absorbed is much higher and the distribution among the various tissues is much wider in animal models. If NAC can treat the symptoms quickly, SURE-NAC™ can potentially improve the long-term quality of life for patients with chronic diseases.

One wide-claim US Patent issued and one filed; additional planned

Raised $277,500 from individual investors

Assembled an experienced management team

Conducted two successful animal tests at Stanford University by Prof. Michael McConnell

Demonstrated a >50% reduction in aortic plaques and 60% reduction in aortic inflammation in heart disease prone mice

Significantly reduced liver fat accumulation, hepatic inflammation and reduced the serum concentration of multiple inflammatory proteins in the same animals

Reduced angiotensin-induced formation of aortic aneurysms and death from ruptured aneurysms in mice

Dr. Tian has many years of experience in product development, marketing and management and is currently the Head of Global Marketing at Trina Solar. Dr. Tian has much experiance in startup companies. She co-founded a startup company called SpectraLane in the year of 2000. Dr. Tian holds a PhD degree in chemistry from Drexel University.

Dr. Arad is an expert in internal medicine, endocrinology, arteriosclerosis, emergency medicine, preventative medicine, the detection of coronary disease and FDA clinical trials design. He has been a practicing physician since 1982 when he began studying factors altering lipoprotein metabolism at Columbia University. Later, at St. Francis Heart Hospital, he investigated how various agents, including NAC, may affect LDL oxidation and function. The results of that study led to the development of this Tiara product. Dr. Arad has a BA degree in Mathematics and a MD degree from the University of Rochester.

Dr. Marlowe has 30 years experience in pharmaceutical development management and research chemistry. From 2003 to 2011, he was Associate Director in the Medicinal Chemistry department at Exelixis Pharmaceuticals, previously with Chiron Corp. and COR Therapeutics where he invented clinical candidate elinogrel. He is the holder of over 25 world and U.S. patents, has BS degrees in chemistry and biology from UC Irvine, a PhD in organic and bioorganic chemistry from UC Berkeley and an NIH sponsored postdoctoral study at Stanford University.

Dr. Dong has over 20 years experience in formulation and material science, specializing in controlled release systems and enhanced oral absorption of therapeutic agents. He is an inventor of 40 granted US Patents. He has acted as the Chief Scientifc Officer at ADDS Pharmaceuticals and the Senior Research Fellow and director at ALZA and Johnson & Johnson. Dr. Dong received his PhD in Bioengineering from the University of Washington and has degrees in Polymetic Material Science from Shanghai University.

Vincent has over 30 years of financial management experience in technology companies, 13 private startup companies and one public company, SDL, Inc. He has raised over $120M of private equity capital and $50M of venture debt. He was instrumental in IntruVert Networks sale to McAfee, Inc. for $100M and held senior financial management roles in IBM, Conner Peripherals, and LSI Logic where he was on the Board of their Japanese joint venture Kawasaki Corporation. He holds an MBA from Harvard University and a BS in Applied Mathematics from Georgia Tech.

Mark is a California Real Estate Broker who in 1982 founded a very successful mortgage brokerage company. He is considered an expert in the field of real estate mortgage lending due to his established money management skills. He raised $50,000,000 for his firm. He received an honorary degree in Business Administration with an emphasis on financing from UC Berkeley.